In contrast, the Albumin To prevenT Infection in chronic liveR failurE (ATTIRE) trial demonstrated that targeted HAS therapy (a median of 200 g of albumin was infused achieving a serum albumin >30 g/L) had no effect on the incidence of infection, renal dysfunction, or mortality compared with standard care (a median of 20 g was given achieving a serum albumin of 25 g/L) (14). Here, ALB is linked to infection.